Tyra Biosciences, Inc.

NasdaqGS TYRA

Tyra Biosciences, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 1,606.80

Tyra Biosciences, Inc. Price to Sales Ratio (P/S) is 1,606.80 on January 14, 2025, a 41.82% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Tyra Biosciences, Inc. 52-week high Price to Sales Ratio (P/S) is 2,883.97 on October 24, 2024, which is 79.49% above the current Price to Sales Ratio (P/S).
Tyra Biosciences, Inc. 52-week low Price to Sales Ratio (P/S) is 1,123.17 on January 17, 2024, which is -30.10% below the current Price to Sales Ratio (P/S).
Tyra Biosciences, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 1,806.80.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: TYRA

Tyra Biosciences, Inc.

CEO	Dr. Todd Harris Ph.D.
IPO Date	Sept. 15, 2021
Location	United States
Headquarters	2656 State Street
Employees	49
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

Key trends

Past 5 years